Close Menu

NEW YORK – Point-of-care diagnostic firm ProciseDx said on Tuesday that it has raised $10.5 million in a Series A financing round led by French diagnostics company Biosynex. 

ProciseDx raised $8.5 million of equity and $2 million of debt to fund ongoing development and commercialization of its point-of-care diagnostic platform. Lead investor Biosynex now owns 37 percent of the company and will join its board, while Nestle Health Science, which previously owned 100 percent of ProciseDx, will remain a significant minority shareholder.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.